GLP-1 Side Effects: What to Expect & How to Manage

What GLP-1 medications do to the body

Glucagon-like peptide-1 receptor agonists, including semaglutide (Wegovy®, Ozempic®, Rybelsus®) and tirzepatide (Mounjaro®, Zepbound®), work by mimicking a gut hormone the body releases after a meal. They slow gastric emptying, blunt appetite signaling in the hypothalamus, and increase glucose-dependent insulin secretion. Most of the side effects people report are downstream of the first mechanism: food sits in the stomach longer than it used to, and the body is not used to that.

Side effects are most pronounced during the first few weeks of treatment and after each dose escalation. They typically taper as the body adapts, though a meaningful minority of patients continue to feel them for months. Reported tolerability differs across the published trials but the broad pattern is consistent: gastrointestinal symptoms dominate, central nervous system effects are mild and usually transient, and rare-but-serious events are real and worth understanding.

Nausea

Nausea is the most common adverse event in every GLP-1 trial, affecting roughly 30 to 45 percent of patients at some point during titration. It tends to be worst in the first 48 to 72 hours after a dose and after a meal that is larger or richer than usual. The mechanism is slowed gastric emptying paired with direct effects on the area postrema in the brainstem.

Smaller, more frequent meals tend to help. So does eating slowly, stopping when 70 percent full rather than fully sated, and avoiding fried, greasy, or very sweet foods on dose day. Hydration matters but cold water tolerated better than warm, and carbonated drinks are often poorly tolerated. Ginger, in tea or capsule form, has reasonable evidence behind it for general nausea. If nausea is severe or paired with vomiting that prevents fluid intake, that is a reason to call the prescriber rather than push through.

Constipation

Constipation affects roughly 10 to 25 percent of patients. Slowed gastric emptying applies to the entire GI tract, not just the stomach, and reduced food intake means less fiber and less stool bulk. The combination is predictable.

Increasing soluble fiber gradually, drinking enough water, and walking after meals all help. A magnesium citrate or magnesium glycinate supplement is a commonly used countermeasure, as is psyllium husk taken with adequate water. Stimulant laxatives like senna are best reserved for short-term use under guidance. If constipation persists more than a week, or if there is severe abdominal pain, fever, or blood in stool, that needs medical evaluation.

Sulfur burps

Burps that taste or smell like rotten eggs are an unusual but well-documented GLP-1 side effect. They come from hydrogen sulfide gas produced by gut bacteria fermenting protein that sits in the upper GI tract longer than normal. Patients describe them as one of the more socially distressing effects.

Smaller protein portions, avoiding sulfur-rich foods on dose day (eggs, garlic, onions, broccoli, red meat), and not lying down within two hours of eating tend to reduce them. Some find that bismuth subsalicylate helps acutely. The phenomenon usually resolves within a few days of onset.

Fatigue

A fraction of patients report low energy or a flat affect in the first weeks. The likely contributors are reduced caloric intake, dehydration from poor fluid tolerance, and electrolyte shifts. Less commonly, it can reflect hypoglycemia in someone on concurrent insulin or sulfonylureas. Persistent unexplained fatigue is worth checking thyroid function, ferritin, and B12, since rapid weight loss can unmask underlying deficiencies.

Less common but serious effects

Acute pancreatitis is uncommon but documented. Persistent, severe abdominal pain that radiates to the back, especially if paired with vomiting, is a reason to seek same-day evaluation and pause the medication. Gallbladder disease, including symptomatic gallstones, occurs at a slightly elevated rate, partly because rapid weight loss itself raises gallstone risk.

Medullary thyroid carcinoma carries a black-box warning based on rodent studies; the human signal remains uncertain but the medication is contraindicated in patients with personal or family history of medullary thyroid cancer or MEN-2. Reports of severe gastroparesis exist, though it is unclear how often the condition is unmasked rather than caused by treatment.

Hair shedding and skin changes

Increased hair shedding occurs in some patients, generally three to four months after weight loss begins, and matches the pattern of telogen effluvium seen with any rapid caloric deficit. Adequate protein, iron, and zinc intake helps. The shedding usually resolves once weight stabilizes.

When to seek medical advice

Call the prescriber for vomiting that prevents keeping fluids down, severe or persistent abdominal pain, signs of dehydration, blood in stool, jaundice, or symptoms suggestive of pancreatitis or gallbladder attack. Seek emergency care for severe abdominal pain with vomiting, chest pain, or signs of a severe allergic reaction. Do not stop or change the dose of a GLP-1 medication without talking to the prescriber first; abrupt discontinuation has its own consequences, particularly for patients also managing type 2 diabetes.

---

Wegovy®, Ozempic®, Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound® are trademarks of Eli Lilly and Company. PepAI is independent.